Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients

Highlights • Telbivudine concurrent with initial chemotherapy can reduce HBV reactivation. • Telbivudine concurrent with chemotherapy was still effective when rituximab was used. • Even if baseline HBV viral loads are high, concurrent treatment is also effective.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical virology 2014-10, Vol.61 (2), p.199-203
Hauptverfasser:	Li, Wenyu, Huang, Ling, Guo, Hanguo, Wei, Xiaojuan, Liang, Zhanli
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Allergy and Immunology Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antiviral Agents - therapeutic use Antiviral therapy Female HBsAg-positive lymphoma HBV reactivation Hepatitis B Surface Antigens - blood Hepatitis B virus Hepatitis B, Chronic - complications Hepatitis B, Chronic - drug therapy Humans Immunocompromised Host Infectious Disease Lymphoma - complications Lymphoma - drug therapy Male Middle Aged Retrospective Studies Telbivudine Telbivudine concurrent with chemotherapy Thymidine - analogs & derivatives Thymidine - therapeutic use Treatment Outcome Virus Activation - drug effects Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Telbivudine concurrent with initial chemotherapy can reduce HBV reactivation. • Telbivudine concurrent with chemotherapy was still effective when rituximab was used. • Even if baseline HBV viral loads are high, concurrent treatment is also effective.
ISSN:	1386-6532 1873-5967
DOI:	10.1016/j.jcv.2014.07.005